Quince Therapeutics (QNCX) News Today $1.76 -0.02 (-1.12%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$1.80 +0.03 (+1.99%) As of 10/24/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock QNCX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Citizens JMP Remains a Buy on Quince Therapeutics (QNCX)1 hour ago | theglobeandmail.comQuince Therapeutics Updates on NALL Study EfficacyOctober 17, 2025 | tipranks.comQuince Therapeutics presents data from patient-reported walking capacity at CNSOctober 10, 2025 | msn.comQuince Therapeutics' (QNCX) Sell (D-) Rating Reaffirmed at Weiss RatingsOctober 10, 2025 | marketbeat.comQuince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual MeetingOctober 9, 2025 | businesswire.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Recommendation of "Buy" from BrokeragesOctober 4, 2025 | marketbeat.comQuince Therapeutics, Inc. (QNCX) Analyst/Investor Day TranscriptOctober 2, 2025 | seekingalpha.comQuince Therapeutics (NASDAQ:QNCX) Stock Price Up 1.2% - Time to Buy?October 1, 2025 | marketbeat.comQuince Therapeutics' (QNCX) "Buy" Rating Reaffirmed at D. Boral CapitalSeptember 26, 2025 | marketbeat.comQuince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling StudySeptember 25, 2025 | businesswire.comQuince Therapeutics, Inc. - Special CallSeptember 24, 2025 | seekingalpha.comQuince Therapeutics to Host Virtual Investor Day on October 2, 2025September 11, 2025 | businesswire.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Receives Average Rating of "Buy" from BrokeragesSeptember 11, 2025 | marketbeat.com806,780 Shares in Quince Therapeutics, Inc. $QNCX Bought by Ieq Capital LLCSeptember 3, 2025 | marketbeat.comQuince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | businesswire.comQuince Therapeutics (NASDAQ:QNCX) Raised to "Hold" at Zacks ResearchAugust 30, 2025 | marketbeat.comQuince Therapeutics Inc News (QNCX) - Investing.comAugust 22, 2025 | investing.comQNCX Q3 EPS Estimate Lifted by Brookline Capital ManagementAugust 17, 2025 | marketbeat.comQuince Therapeutics (NASDAQ:QNCX) Receives "Buy" Rating from D. Boral CapitalAugust 17, 2025 | marketbeat.comQNCX FY2029 EPS Increased by Brookline Capital ManagementAugust 16, 2025 | marketbeat.comQuince Therapeutics (NASDAQ:QNCX) Price Target Cut to $8.00 by Analysts at JMP SecuritiesAugust 13, 2025 | marketbeat.comQuince Therapeutics (NASDAQ:QNCX) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPSAugust 12, 2025 | marketbeat.comQuince Therapeutics price target lowered to $8 from $9 at Citizens JMPAugust 12, 2025 | msn.comQuince Therapeutics Reports Q2 2025 Financial ResultsAugust 12, 2025 | msn.comQuince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial ResultsAugust 11, 2025 | businesswire.comQuince Therapeutics (QNCX) Projected to Post Earnings on TuesdayAugust 6, 2025 | marketbeat.comJMP Securities Begins Coverage on Quince Therapeutics (NASDAQ:QNCX)August 6, 2025 | marketbeat.comQuince Therapeutics (NASDAQ:QNCX) Now Covered by Analysts at Citizens JmpAugust 6, 2025 | marketbeat.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Short Interest Up 64.5% in JulyAugust 6, 2025 | marketbeat.comJMP Securities Initiates Coverage of Quince Therapeutics (QNCX) with Market Outperform RecommendationAugust 5, 2025 | msn.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Recommendation of "Buy" by AnalystsJuly 21, 2025 | marketbeat.comBrookline Capital Management Comments on QNCX Q3 EarningsJuly 21, 2025 | marketbeat.comQuince Therapeutics, Inc. (QNCX) - Yahoo FinanceJuly 17, 2025 | finance.yahoo.comQuince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-TelangiectasiaJuly 16, 2025 | businesswire.comQuince Therapeutics Appoints Leading Immunologist Dr. Hassan ...July 12, 2025 | finance.yahoo.comQuince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory BoardJuly 10, 2025 | businesswire.comQuince Therapeutics to Participate at A-T Society's 2025 A-T Clinical Research ConferenceJune 25, 2025 | businesswire.comQuince Therapeutics Announces Closing of Up to $22 Million Private Placement of SecuritiesJune 18, 2025 | businesswire.comQuince Therapeutics raises $11.5 million in private placementJune 14, 2025 | investing.comQuince Therapeutics Raises $11.5M in Private PlacementJune 13, 2025 | tipranks.comQuince Therapeutics' (QNCX) Buy Rating Reaffirmed at D. Boral CapitalJune 13, 2025 | marketbeat.comQuince Therapeutics Announces Pricing of Up to $22 Million Private Placement of SecuritiesJune 12, 2025 | businesswire.comQuince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-TelangiectasiaJune 3, 2025 | businesswire.comQuince Therapeutics: Data In Ataxia-Telangiectasia Scheduled For Early 2026May 15, 2025 | seekingalpha.comQuince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 14, 2025 | finance.yahoo.comQuince Therapeutics to Present at Citizens Life Sciences ConferenceApril 30, 2025 | businesswire.comQuince Therapeutics to Present at Jones Healthcare and Technology Innovation ConferenceApril 3, 2025 | businesswire.comQuince Therapeutics (QNCX) Expected to Announce Earnings on MondayMarch 31, 2025 | marketbeat.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Short Interest Down 33.5% in MarchMarch 30, 2025 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD)March 27, 2025 | markets.businessinsider.com Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QNCX Media Mentions By Week QNCX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. QNCX News Sentiment▼1.890.93▲Average Medical News Sentiment QNCX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. QNCX Articles This Week▼12▲QNCX Articles Average Week Get the Latest News and Ratings for QNCX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Quince Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Korro Bio News Kamada News Invivyd News Aura Biosciences News Replimune Group News LB Pharmaceuticals News Larimar Therapeutics News Annexon News DiaMedica Therapeutics News Editas Medicine News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:QNCX) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
